A recently published study by FMI expects the global hematopoietic stem cell transplantation market to augment at an 8% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 15 Billion is expected for the market. The hematopoietic stem cell transplantation market has grown fast in recent years and is expected to develop substantially over the projected period. According to the GLOBOCAN 2018 report, the global incidence of leukaemia in 2018 was predicted to be 437,033 new cases and about 309,006 deaths.
Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16462
According to the World Health Organization (WHO), more than 2000 cord blood hematopoietic stem cell transplants are performed each year (WHO). Hematopoietic stem cells can be found in bone marrow and blood (HSCs). They are also known as hematopoietic progenitor cells (HPCs). Platelets, white blood cells, and red blood cells, among other blood types, can be produced by hematopoietic stem cells. In the treatment of malignant (such as lymphoma and leukaemia) and non-malignant (such as bone marrow failure and hemoglobinopathies), these cells are used to rebuild or replace a patient’s hematopoietic system.
Another important element impacting the growth rate of the hematopoietic stem cell transplantation market is growing healthcare spending, which aids in infrastructure improvement. Numerous government organisations intend to improve healthcare infrastructure by boosting financing, which would have an impact on market dynamics. Because of the increased success rate of transplants and growing healthcare spending in this area, North America leads the hematopoietic stem cell transplantation market. The presence of significant important players would accelerate the industry’s growth rate in this area.
Key Takeaways from the Market Study
- FMI projects the global hematopoietic stem cell transplantation market to expand at an 8% value CAGR by 2032
- The global hematopoietic stem cell transplantation market is estimated at a market value of US$ 7 Billion
- The global hematopoietic stem cell transplantation market is expected to garner a market value of US$ 15 Billion
- North America is expected to grow at a CAGR of 7.9% in the assessment period 2023-2033.
- Europe is expected to grow at a CAGR of 7.6% in the assessment period 2023-2033.
- Asia Pacific is expected to grow at a CAGR of 7.5% in the assessment period 2023-2033.
- The bone marrow segment is expected to hold the largest market share for hematopoietic stem cell transplantation in the forecast period 2023-2033
“The market’s expansion is being propelled by an increase in the number of R&D activities. This will create advantageous chances for the expansion of the hematopoietic stem cell transplantation market. Additionally, growing medication approvals and launches will accelerate the market’s growth pace,” says an analyst at FMI.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16462
Market Competition
Key players in the Hematopoietic Stem Cell Transplantation market are Key players in the hematopoietic stem cell transplantation market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio and Talaris Therapeutics.
Recent Developments:
- In December 2022, despite missing the primary endpoint, Takeda’s Phase 3 AURORA study shows that maribavir has a clinically meaningful and long-lasting effect on Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant patients.
- In November 2022, Lonza, a trusted partner in the pharmaceutical, biotech, and nutraceutical industries, has introduced an innovative new capsule solution for enteric drug administration. The Capsugel® EnprotectTM capsule does not dissolve in the stomach and releases its contents only in the intestine. By eliminating the need for extra capsule coating or sealing, Capsugel® EnprotectTM capsules greatly simplify the medicinal product production process.
Key Segments Profiled in the Hematopoietic Stem Cell Transplantation Market Industry Survey
By Transplant Type:
- Allogeneic
- Autologous
By Indication:
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Other Non-Malignant Disorders
By Application:
- Bone Marrow Transplant
- Peripheral Blood Stem Cells Transplant
- Cord Blood Transplant
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-16462
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global hematopoietic stem cell transplantation market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the hematopoietic stem cell transplantation market, the market is segmented on the basis of transplant type (allogeneic and autologous), by indication (acute myeloid leukaemia, acute lymphoblastic leukaemia, hodgkin lymphoma, non-hodgkin lymphoma, multiple myeloma and other non-malignant disorders), application (bone marrow transplant, peripheral blood stem cells transplant and cord blood transplant) across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
